NeuroSense Therapeutics Ltd.
corporate_fare Company Profile
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for NRSN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NRSN spans 6-K, F-3/A, 4.
Recent high-impact activity:
- NeuroSense Signs PrimeC Supply Collaboration Targeting First Revenue in H1 2027
- NeuroSense Secures November 10 Nasdaq Hearing Date; Bid-Price Compliance Regained
- Nasdaq Moves to Delist NeuroSense Over $35M Market Value Shortfall; Company to Appeal
- NeuroSense Reports H1 2026 Loss, $0.2M Cash, and Going Concern Warning
- NeuroSense Finalizes 1-for-20 Reverse Split, Effective September 14
Financial Snapshot
Short Interest & Short Volume
1.20 days to coverFINRA reported short interest of 26,105 shares in NRSN as of the October 15, 2026 settlement, a 2.9% decrease from the prior period — about 1.2 days to cover at its recent average daily volume. On October 29, 2026, 50.8% of NRSN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NRSN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-30.
ATM Capacity Reduced to $3.8M · Nasdaq Delisting Risk Disclosed
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NRSN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.